Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 17, 2023

Primary Completion Date

February 9, 2024

Study Completion Date

February 9, 2024

Conditions

Interstitial Lung DiseaseChronic Kidney Diseases

Interventions

BIOLOGICAL

AD-214

AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.

OTHER

Placebo

Trial Locations (1)

CMAX Clinical Research Pty Ltd, Adelaide